BioCentury | Oct 8, 2012
Clinical News

MDCO-2010: Development discontinued

...Medicines Co. gained MDCO-2010 through its 2008 acquisition of Curacyte Discovery GmbH, a subsidiary of Curacyte AG...
BioCentury | Sep 24, 2012
Finance

Hopp stays the course

...deal facilitated by dievini Hopp (see BioCentury, March 2, 2009) . Among other recent setbacks, Curacyte AG...
...that acts as a nitric oxide scavenger. AX200 is a recombinant granulocyte-colony stimulating factor (G-CSF). Curacyte...
...update on its plans. dievini Hopp initially invested €12 million ($15.7 million) as part of Curacyte's...
BioCentury | Oct 24, 2011
Clinical News

MDCO-2010: Phase IIa data

...Medicines Co. gained MDCO-2010 through its 2008 acquisition of Curacyte Discovery GmbH, a subsidiary of Curacyte AG...
BioCentury | Sep 5, 2011
Clinical News

Hemoximer pyridoxalated hemoglobin polyoxyethylene: Interim Phase III data

...planned 454 patients, will not meet the primary endpoint of all-cause mortality at 28 days. Curacyte...
...plus vasopressor therapy in patients with catecholamine-resistant distributive shock for a maximum of 150 hours. Curacyte...
...said hemoximer is the company's only asset. The company would not comment on next steps. Curacyte AG...
BioCentury | Aug 30, 2011
Clinical News

Curacyte ends Phase III trial of shock candidate

...distributive shock for a maximum of 150 hours. Hemoximer is a nitric oxide (NO) scavenger. Curacyte...
BioCentury | Apr 4, 2011
Clinical News

Hemoximer pyridoxalated hemoglobin polyoxyethylene: Phase III ongoing

...plus vasopressor therapy in patients with catecholamine-resistant distributive shock for a maximum of 150 hours. Curacyte AG...
BioCentury | Feb 8, 2010
Strategy

Medicines Co. chronicles

...its recent deal for ApoA-I Milano from Pfizer Inc. (NYSE:PFE) as well as acquisitions of Curacyte...
...not feasible or desirableC. 8/5/08 - Acquires Curacyte Discovery GmbH for €14.5M ($22.6M), thus obtaining Curacyte's...
BioCentury | Feb 8, 2010
Strategy

Spending for a rainy day

...the $42 million paid upfront. In an earlier pipeline filling, Medicines Co. acquired Curacyte AG 's Curacyte...
...small molecule serine protease inhibitor that was in preclinical testing to prevent surgical blood loss. Curacyte...
...Germany Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Lexington, Mass. Curacyte AG...
BioCentury | Jun 15, 2009
Clinical News

Hemoximer Pyridoxalated hemoglobin polyoxyethylene: Phase III started

...a continuous IV infusion in more than 450 patients unresponsive to standard therapy with catecholamines. Curacyte AG...
BioCentury | Jan 8, 2009
Distillery Therapeutics

Indication: Cancer

...inhibitors and evaluating the candidates in preclinical CLL models. CD 160130, a PDE4 inhibitor from Curacyte AG...
Items per page:
1 - 10 of 49
BioCentury | Oct 8, 2012
Clinical News

MDCO-2010: Development discontinued

...Medicines Co. gained MDCO-2010 through its 2008 acquisition of Curacyte Discovery GmbH, a subsidiary of Curacyte AG...
BioCentury | Sep 24, 2012
Finance

Hopp stays the course

...deal facilitated by dievini Hopp (see BioCentury, March 2, 2009) . Among other recent setbacks, Curacyte AG...
...that acts as a nitric oxide scavenger. AX200 is a recombinant granulocyte-colony stimulating factor (G-CSF). Curacyte...
...update on its plans. dievini Hopp initially invested €12 million ($15.7 million) as part of Curacyte's...
BioCentury | Oct 24, 2011
Clinical News

MDCO-2010: Phase IIa data

...Medicines Co. gained MDCO-2010 through its 2008 acquisition of Curacyte Discovery GmbH, a subsidiary of Curacyte AG...
BioCentury | Sep 5, 2011
Clinical News

Hemoximer pyridoxalated hemoglobin polyoxyethylene: Interim Phase III data

...planned 454 patients, will not meet the primary endpoint of all-cause mortality at 28 days. Curacyte...
...plus vasopressor therapy in patients with catecholamine-resistant distributive shock for a maximum of 150 hours. Curacyte...
...said hemoximer is the company's only asset. The company would not comment on next steps. Curacyte AG...
BioCentury | Aug 30, 2011
Clinical News

Curacyte ends Phase III trial of shock candidate

...distributive shock for a maximum of 150 hours. Hemoximer is a nitric oxide (NO) scavenger. Curacyte...
BioCentury | Apr 4, 2011
Clinical News

Hemoximer pyridoxalated hemoglobin polyoxyethylene: Phase III ongoing

...plus vasopressor therapy in patients with catecholamine-resistant distributive shock for a maximum of 150 hours. Curacyte AG...
BioCentury | Feb 8, 2010
Strategy

Medicines Co. chronicles

...its recent deal for ApoA-I Milano from Pfizer Inc. (NYSE:PFE) as well as acquisitions of Curacyte...
...not feasible or desirableC. 8/5/08 - Acquires Curacyte Discovery GmbH for €14.5M ($22.6M), thus obtaining Curacyte's...
BioCentury | Feb 8, 2010
Strategy

Spending for a rainy day

...the $42 million paid upfront. In an earlier pipeline filling, Medicines Co. acquired Curacyte AG 's Curacyte...
...small molecule serine protease inhibitor that was in preclinical testing to prevent surgical blood loss. Curacyte...
...Germany Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Lexington, Mass. Curacyte AG...
BioCentury | Jun 15, 2009
Clinical News

Hemoximer Pyridoxalated hemoglobin polyoxyethylene: Phase III started

...a continuous IV infusion in more than 450 patients unresponsive to standard therapy with catecholamines. Curacyte AG...
BioCentury | Jan 8, 2009
Distillery Therapeutics

Indication: Cancer

...inhibitors and evaluating the candidates in preclinical CLL models. CD 160130, a PDE4 inhibitor from Curacyte AG...
Items per page:
1 - 10 of 49